AGEN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strategic Financing & Program PivotThe private placement explicitly underwrites a strategic pivot to a global Phase 3 ROBBIN neoadjuvant colon cancer program and funds operations into 2027 (or longer if warrants exercised). This provides multi-quarter runway tied to a focused, larger-market development path and concentrates resources on higher-return indications.
TTM Profitability And Revenue ImprovementA meaningful trailing‑twelve‑month swing to reported profitability and recent revenue growth indicates the company is operating closer to break‑even and improving gross economics. If sustained, these trends support longer-term R&D funding ability and reduce execution risk versus a history of deep losses.
Debt And Warrant Extensions Ease Near-term PressureNegotiated extensions of debt maturities and warrant expirations push imminent cash obligations further out and provide flexibility. Registering shares tied to new warrants improves liquidity for holders and lowers immediate refinancing stress, offering durable breathing room while clinical milestones are advanced.
Bears Say
Negative Stockholders' EquityPersistent negative equity constrains financial flexibility, distorts leverage metrics, and raises the likelihood of covenant or credit-market stress. Over a multi‑quarter horizon, this structural capital weakness increases dependence on external financing and limits the company's ability to absorb setbacks without dilutive raises.
Ongoing Negative Operating And Free Cash FlowMulti‑year negative operating and free cash flow indicate the business is not self‑funding and remains dependent on partner payments and capital markets. This persistent cash burn creates execution risk for multi‑year clinical programs and elevates the probability of additional equity or debt issuance, diluting existing holders.
Governance Transition And Dilution RiskThe simultaneous reliance on equity‑linked financings and the resignation of the principal accounting officer create two durable risks: ongoing dilution from capital raises and potential near‑term disruption to financial controls and reporting. Both factors can impair execution and investor confidence across the clinical timeline.
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Currently, no data Available
What is Agenus’s market cap?
Agenus’s market cap is CHF271.47M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Aug 06, 2026 which is tomorrow.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on May 11, 2026. The company reported CHF0.825 earnings per share for the quarter, missing the consensus estimate of CHF1.698 by -CHF0.873.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is 0.04.
How many shares outstanding does Agenus have?
Currently, no data Available
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of CHF0.825 in its last earnings report, missing expectations of CHF1.698. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in CH:AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF17.93 (― Upside)
CHF17.93 (― Upside)
Blogger Sentiment
Bullish
CH:AGEN Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.87%
Trailing 12-Months
Company Description
Agenus
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
―Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―